Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Net Margin (2024 - 2025)

Xilio Therapeutics' Net Margin history spans 2 years, with the latest figure at 10.12% for Q3 2025.

  • For Q3 2025, Net Margin rose 64220.0% year-over-year to 10.12%; the TTM value through Sep 2025 reached 137.64%, changed N/A, while the annual FY2024 figure was 954.95%, N/A changed from the prior year.
  • Net Margin for Q3 2025 was 10.12% at Xilio Therapeutics, up from 177.71% in the prior quarter.
  • Across five years, Net Margin topped out at 10.12% in Q3 2025 and bottomed at 790.55% in Q4 2024.